Han Lei

Han Lei

Auto-generated profile, based on publicly available information

Han Lei

Department of Cardiology, First Affiliated Hospital of Chongqing Medical University, Chongqing, PR China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YYYuan Yang
Yuan Yang
FZFan Zhang
Fan Zhang
LSLaura Skrip
Laura Skrip
HLHan Lei
Han Lei
SLSu Xin Luo
Su Xin Luo
DHDayi Hu
Dayi Hu
A previous meta-analysis of randomized controlled studies that were not designed to investigate cancer as a primary outcome suggested that ARB-based therapy is associated with increased risk of cancer; however, results of recent observational studies considering the association have been contradictory. This study sought to evaluate the association between angiotensin receptor blocker (ARB)-based therapy and risk of cancer by conducting a meta-analysis of observational studies. Relevant articles published before February 2014 were identified by searching PubMed and the Cochrane Library. Pooled relative risks (RRs) were determined using a random effects model and were used to assess the strength of association between use of ARB-based therapy and risk of cancer. Six retrospective cohort studies involving a total of 3,827,109 participants and four case-control studies involving a total of 193,029 cases were included. The present study found that ARB-based therapy was not significantly associated with an increased risk of cancer (RR = 0.87, 95%CI: [0.75, 1.01]). However, an analysis including only cohort studies suggested a significantly decreased risk of cancer among individuals with any history of ARB use as compared to those with no history of ARB use (RR = 0.80, 95%CI: [0.55, 0.95]); no significant association was found between ARB use and risk of cancer when the case-control studies were separately considered (RR = 1.03, 95%CI: [0.93, 1.13]). Subgroup analyses showed that use of ARB-based therapy was associated with decreased risk of lung cancer (RR = 0.81, 95%CI: [0.69, 0.94]); however, no significant associations were found with the other cancer sites investigated. Furthermore, no association was observed upon adjustment by type of ARB drug. No publication bias was detected. Overall, ARB-based therapy was not associated with increased risk of cancer. However, its use may be related to decreased incidence of lung cancer; this finding should be considered carefully and confirmed with further studies.

1 September 2018 in Life Sciences
Verified
Journal Article
Closed access
GYGuiquan Yu
Guiquan Yu
JCJing Chen
Jing Chen
SLSiyu Li
Siyu Li
PPPeng Pu
Peng Pu
WHWei Huang
Wei Huang
HLHan Lei
Han Lei

15 October 2012 in JACC
Verified
Journal Article
Closed access
PDF file
QWQi Wu
Qi Wu
QZQi Zhou
Qi Zhou
QZQue Zhu
Que Zhu
SRShunkang Rong
Shunkang Rong
QWQi Wang
Qi Wang
JHJing Huang
Jing Huang